ZOM Stock Cash Flow Statements

Zomedica Corp Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Zomedica Corp Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30

cash flows from operating activities:
net income	-22,406,000			-6,385,000	-2,809,000	-4,996,000	-5,273,000	-3,937,000	-3,289,992	-6,345,687
adjustments for:
depreciation	292,000			164,000	156,000	109,000	79,000	82,000	90,328	60,444
amortization - intangible assets	1,578,000			1,199,000	1,076,000	1,045,000	758,000	737,000	737,893	46,732
impairment loss
gain on disposal of property and equipment
gain on conversion of notes receivable	0
stock-based compensation	1,105,000			1,765,000	1,439,000	1,919,000	2,492,000	2,041,000	2,589,434	1,437,779
non cash portion of rent benefit	189,000
accretion/amortization of available-for-sale securities	-493,000			-654,000	-500,000
deferred tax expense
change in assets and liabilities, net of acquisitions:
purchased inventory	291,000			-731,000	-371,000	-1,065,000	-1,567,000	-1,005,000		-1,081,525
prepaid expenses and deposits	883,000			-1,022,000	-135,000	-920,000	-538,000	128,000	-68,745	-498,306
trade receivables	120,000			144,000	159,000	-346,000	-69,000	-27,000
other receivables	155,000			263,000	-403,000	-62,000	156,000	-25,000	-41,721	10,142
accounts payable and accrued liabilities	1,469,000			721,000	434,000	2,728,000	410,000	-118,000	-1,804,208	1,369,671
accrued income tax	-52,000			46,000	146,000	0	-176,000	-23,000
deferred tax benefits
other current liabilities	16,000			-16,000	20,000	-208,000	44,000	-40,000
customer contract liabilities	3,000			116,000	-30,000	106,000	10,000	-35,000
other liabilities	-490,000			134,000	-533,000	-22,000	0	30,000
net cash from operating activities	-5,015,000			-4,257,000	-2,383,000	-2,770,000	-4,046,000	-2,471,000	-4,901,352	-4,997,962

cash flows from investing activities:
proceeds on sale of (investment in) available-for-sale securities
investment in debt security	0			-1,750,000	0	0
investment in property and equipment	-115,000			-113,000	-204,000	-432,000	-68,000	-83,000	-50,163	-54,321
acquisition of intangibles	-30,000			-4,000,000	-96,000
investment in construction in progress
investment in acquisitions, net of cash acquired
net cash from investing activities	-3,829,000			-14,792,000	-15,351,000	-138,886,000	-1,437,000	-206,000	-71,583,069	-201,021
cash flows from financing activities:
cash received from warrant exercises					0				23,473	1
net cash from financing activities					0				23,923	400,210
decrease in cash and cash equivalents	-8,844,000
effect of exchange rate changes on cash
cash and cash equivalents, beginning of year	0			27,399,000	0	0	0	194,952,000
cash and cash equivalents, end of period	-8,831,000	-6,168,000	19,598,000	8,353,000					-76,458,835	-4,798,773
noncash activities:
change in fair value of available-for-sale securities, net of tax	416,000			283,000	-66,000
transfer of construction in progress into property and equipment and intangibles	655,000			401,000	-464,000
transfer of inventory into property and equipment	114,000			738,000	40,000	3,734,000	311,000	246,000	346,500
supplemental cash flow information:
interest received on available-for-sale securities
(gain) loss on disposal of property and equipment
deferred tax liabilities					-1,037,000	-658,000	-382,000	-279,000
investment in available-for-sale securities				-8,072,000
interest received				783,000	1,182,000	790,000	-294,000	-90,000	-730,572	340,448
cash from operating activities
cash from investing activities
increase in cash and cash equivalents				-19,049,000	-17,734,000	-141,648,000	-5,483,000	-2,677,000	-76,460,498	-4,798,773
cash and cash equivalents, beginning of period									0	0
●
non cash portion of rent expense				-1,000	7,000	0
capital				217,000
consumables
other
total revenue				399,000
gain on other assets
gain on extinguishment of debt									0	0
cash proceeds from issuance of common shares and warrants
cash paid for shares and warrant issuance costs
cash received from stock option exercises									451	400,208
cash and cash equivalents, end of year					-17,696,000	-141,668,000	-5,574,000	192,337,000
deferred financing fees charged to stock issuance costs
net equity effect of preferred share exchange									0
adjustments for
loss on disposal of property and equipment						0			841	4,806
loss on other assets									-6,054	0
(gain) loss on right-of-use assets
change in non-cash operating working capital, net of acquisitions
investment in securities
investment in assets purchased
accounts receivable recorded in intercompany account
change in non-cash operating working capital
investment in intangibles									-133,487	-146,850
investment in assets in process
noncash investing and financing activities
loss on sale of property and equipment
non-cash portion of rent expense									1,900	656
change in non-cash operating working capital, net of acquisition
inventory
cash from sale of property and equipment									0	150
cash from lease cancellation or modification
investment in subsidiary acquisition, net of cash acquired
proceeds from issuance of common shares, warrants and pre-funded warrants									0	0
cash received from shares to be issued
cash paid on stock issuance costs									-1	1
deferred financing fees charge to stock issuance costs
interest paid
trade receivable										-2,674
cash received for government loan
account receivable recorded in intercompany account

We provide you with 20 years of cash flow statements for Zomedica Corp stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Zomedica Corp stock. Explore the full financial landscape of Zomedica Corp stock with our expertly curated income statements.

The information provided in this report about Zomedica Corp stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.